CDK4 and head and neck squamous cell carcinoma: Other ongoing clinical trials for ICI and CDK4/6 inhibitors in patients with recurrent/metastatic HNSCC include the combination abemaciclib/pembrolizumab (NCT03938337) and palbociclib/avelumab/cetuximab (NCT03498378).